Drug intelligence / Profile preview

compound 066

Development stage: Preclinical
Lead developer: Universidad Central
Modality: Small Molecules

Overview

Compound 066 is a synthetic chalcone derivative identified as a potent antiproliferative agent against ovarian cancer. Developed through 3D-QSAR modeling (CoMFA and CoMSIA) and validated experimentally, it demonstrates significant growth-inhibitory activity against the A2780 ovarian cancer cell line. Its mechanism of action involves the induction of reactive oxygen species (ROS) and the upregulation of heme oxygenase-1 (HO-1), which leads to increased intracellular glutathione levels. Notably, this induction occurs independently of the canonical Nrf2 signaling pathway. The compound is particularly effective against chemoresistant ovarian cancer models, making it a promising candidate for further oncological drug development.

Other names: Compound 066Compound066Compound-066

Targets

HMOX1 (Heme oxygenase 1)

Beyond the preview

Go deeper on compound 066.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 066.

Explore the full profile